H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Pipeline Review, H1 2018
Summary
According to the recently published report 'H+ Transporting Two Sector ATPase - Pipeline Review, H1 2018'; H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - ATP synthase (EC 3.6.3.14) is an important enzyme that creates the energy storage molecule adenosine triphosphate (ATP). The majority of cellular energy in the form of adenosine triphosphate (ATP) is synthesized by the ubiquitous F1F0 ATP synthase. Power for ATP synthesis derives from an electrochemical proton (or Na+) gradient, which drives rotation of membranous F0 motor components.
The report 'H+ Transporting Two Sector ATPase - Pipeline Review, H1 2018' outlays comprehensive information on the H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II and Preclinical stages are 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal and Immunology which include indications Tuberculosis, Leprosy, Plaque Psoriasis (Psoriasis Vulgaris), Pulmonary Tuberculosis and Ulcerative Colitis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14)
- The report reviews H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics and enlists all their major and minor projects
- The report assesses H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics
Reasons to buy- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Introduction
- Global Markets Direct Report Coverage
- H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Overview
- H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Companies Involved in Therapeutics Development
- Johnson & Johnson
- Lycera Corp
- H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Drug Profiles
- bedaquiline fumarate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- LYC-30937 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Inhibit F0F1-ATP Synthase for Tuberculosis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit ATP Synthase for Tuberculosis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- TMC-207 Back Up - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Dormant Products
- H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Product Development Milestones
- Featured News & Press Releases
- Apr 25, 2017: Janssen Files NDA in Japan for Multidrug-Resistant Tuberculosis Drug Bedaquiline Fumarate
- Dec 07, 2016: Lycera Announces Initiation of Phase 2 UPRISE Clinical Trial of LYC-30937-EC for Patients with Moderate Psoriasis
- Dec 01, 2016: China Food And Drug Administration Approves Sirturo (Bedaquiline) For Patients With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
- Aug 22, 2016: Lycera Announces Initiation of Phase 2 Clinical Trial of LYC-30937-EC in Patients with Ulcerative Colitis
- Jun 06, 2016: Speeding up drug discovery to fight tuberculosis
- Mar 18, 2016: Lycera Announces Presentation of Positive Preclinical Results for Lead Candidate LYC-30937 at the 11th Congress of the European Crohn’s and Colitis Organization (ECCO)
- Aug 24, 2015: Janssen’s SIRTURO to be commissioned by NHS England for the treatment of multi-drug resistant tuberculosis
- Apr 30, 2015: Lycera Initiates Phase 1 Clinical Trial of LYC-30937, a First-In-Class ATPase Modulator for Inflammatory Bowel Disease
- Nov 06, 2014: Janssen Collaborates for Continued Evaluation of Multidrug-Resistant Tuberculosis Treatment Regimens with SIRTURO (bedaquiline)
- Oct 14, 2014: Bedaquiline Found Effective Against Tuberculosis In Indian Patients: Hinduja Hospital says
- Mar 06, 2014: SIRTURO (bedaquiline) Receives Conditional Approval in the European Union for the Treatment of Multi-Drug Resistant Tuberculosis
- Dec 20, 2013: SIRTURO Receives Positive Opinion from the Committee for Medicinal Products for Human Use as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis
- Dec 19, 2013: Pharmstandard announces registration of Sirturo for MDR-TB
- Jun 13, 2013: WHO Issues Interim Guidance On Bedaquiline To Treat Multidrug-Resistant Tuberculosis
- Dec 31, 2012: FDA Grants Accelerated Approval For Sirturo As Part of Combination Therapy To Treat Adults With Pulmonary Multi-drug Resistant Tuberculosis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development by Stage of Development, H1 2018
- Number of Products under Development by Therapy Areas, H1 2018
- Number of Products under Development by Indication, H1 2018
- Number of Products under Development by Companies, H1 2018
- Products under Development by Companies, H1 2018
- Number of Products under Investigation by Universities/Institutes, H1 2018
- Products under Investigation by Universities/Institutes, H1 2018
- Number of Products by Stage and Mechanism of Actions, H1 2018
- Number of Products by Stage and Route of Administration, H1 2018
- Number of Products by Stage and Molecule Type, H1 2018
- Pipeline by Johnson & Johnson, H1 2018
- Pipeline by Lycera Corp, H1 2018
- Dormant Projects, H1 2018
- List of Figures
- Number of Products under Development by Stage of Development, H1 2018
- Number of Products under Development by Therapy Areas, H1 2018
- Number of Products under Development by Top 10 Indications, H1 2018
- Number of Products by Stage and Mechanism of Actions, H1 2018
- Number of Products by Stage and Route of Administration, H1 2018
- Number of Products by Stage and Molecule Type, H1 2018